Amarin Corporation plc (AMRN)
Amarin Corporation plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Dublin, DU, IE. The stock last traded at $14.01, down 0.71% on the session, giving a market capitalisation of $289.8M. On trailing twelve-month figures it carries a trailing P/E of -9.81, a net margin of -14.6%. Its beta of 0.77 implies it has historically moved less than the broad market.
Amarin Corporation plc is a pharmaceutical firm dedicated to the research, development, and commercialization of therapeutic solutions for cardiovascular diseases. Its operations span several international regions, including the United States, Germany, Canada, Lebanon, and the United Arab Emirates. The company's flagship product is VASCEPA, an omega-3 fatty acid formulation available by prescription only. This medication acts as an adjunctive therapy to diet, designed to decrease elevated triglyceride levels in adult patients suffering from severe hypertriglyceridemia. Amarin primarily distributes its offerings through wholesale channels and specialized pharmacy providers. Furthermore, the company has entered into a collaboration with Mochida Pharmaceutical Co., Ltd. to advance the development and market introduction of drug products and new indications derived from Vascepa's active pharmaceutical ingredient, which encompasses omega-3 acid and eicosapentaenoic acid. Established in 1989 as Ethical Holdings plc, the organization rebranded to Amarin Corporation plc in 1999. Its corporate headquarters are located in Dublin, Ireland.
Amarin Corporation plc is most often compared with the following Healthcare names: